|
2023-08-11 |
2023-08-01 |
S
Sale
|
Chief Executive Officer
Officer
|
37,721
-30.4%
486.78
US$4,655,205
|
37,721
-30.4%
|
486.78
|
US$4,655,205
|
|
|
2023-08-11 |
2023-08-01 |
S
Sale
|
Deputy GC
Officer
|
1,586
-27.5%
95.06
US$1,395,353
|
1,586
-27.5%
|
95.06
|
US$1,395,353
|
|
|
2023-08-11 |
2023-08-01 |
S
Sale
|
Chief Medical Officer
Officer
|
41,295
+18.2%
413.46
US$1,973,319
|
41,295
+18.2%
|
413.46
|
US$1,973,319
|
|
|
2023-08-11 |
2023-08-01 |
S
Sale
|
Chief Financial Officer
Officer
|
9,434
-8.5%
0.94
US$8,868
|
9,434
-8.5%
|
0.94
|
US$8,868
|
|
|
2022-08-05 |
2022-08-03 |
S
Sale
|
Chief Scientific Officer
Officer
|
4,463
-4.9%
1.72
US$7,676
|
4,463
-4.9%
|
1.72
|
US$7,676
|
|
|
2022-08-05 |
2022-08-03 |
S
Sale
|
Chief Financial Officer
Officer
|
5,980
-5.1%
1.72
US$10,286
|
5,980
-5.1%
|
1.72
|
US$10,286
|
|
|
2022-08-05 |
2022-08-03 |
S
Sale
|
Chief Medical Officer
Officer
|
4,463
-6.5%
1.72
US$7,676
|
4,463
-6.5%
|
1.72
|
US$7,676
|
|
|
2022-08-05 |
2022-08-03 |
S
Sale
|
Chief Executive Officer
Officer
|
10,594
-9.6%
1.72
US$18,222
|
10,594
-9.6%
|
1.72
|
US$18,222
|
|
|
2022-08-05 |
2022-08-03 |
S
Sale
|
Chief Business Officer
Officer
|
5,676
-14.9%
1.72
US$9,763
|
5,676
-14.9%
|
1.72
|
US$9,763
|
|
|
2022-01-14 |
2021-07-21 |
S
Sale
|
Chief Medical Officer
Officer
|
14,809
-32.9%
6.10
US$90,335
|
14,809
-32.9%
|
6.10
|
US$90,335
|
|
|
2022-01-14 |
2021-07-21 |
S
Sale
|
Chief Scientific Officer
Officer
|
26,325
-32.9%
6.10
US$160,582
|
26,325
-32.9%
|
6.10
|
US$160,582
|
|
|
2022-01-14 |
2021-07-21 |
S
Sale
|
Chief Executive Officer
Officer
|
33,500
-38.1%
6.10
US$204,350
|
33,500
-38.1%
|
6.10
|
US$204,350
|
|
|
2022-01-14 |
2021-07-21 |
S
Sale
|
Non-Executive Director
|
127,778
-49.7%
6.10
US$779,446
|
127,778
-49.7%
|
6.10
|
US$779,446
|
|
|
2022-01-14 |
2021-07-21 |
S
Sale
|
Chief Financial Officer
Officer
|
19,854
-20.0%
6.10
US$121,109
|
19,854
-20.0%
|
6.10
|
US$121,109
|
|
|
2022-01-14 |
2021-07-21 |
S
Sale
|
Chief Legal Officer
Officer
|
26,325
-32.9%
6.10
US$160,582
|
26,325
-32.9%
|
6.10
|
US$160,582
|
|
|
2021-06-11 |
2021-06-11 |
S
Sale
|
Non-Executive Director
|
15,273
-5.6%
7.61
US$116,226
|
15,273
-5.6%
|
7.61
|
US$116,226
|
|
|
2021-06-11 |
2021-06-10 |
S
Sale
|
Non-Executive Director
|
234,727
-47.3%
7.66
US$1,798,619
|
234,727
-47.3%
|
7.66
|
US$1,798,619
|
|
|
2021-02-18 |
2021-02-16 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
1,000
-1.1%
11.35
US$11,350
|
1,000
-1.1%
|
11.35
|
US$11,350
|
|
|
2021-02-09 |
2021-02-08 |
PlS
Planned sale
|
Chief Executive Officer
Executive Director
|
2,500
-0.9%
12.50
US$31,250
|
2,500
-0.9%
|
12.50
|
US$31,250
|
|
|
2021-02-09 |
2021-02-08 |
PlS
Planned sale
|
See Remarks
Officer
|
1,500
-1.5%
12.45
US$18,675
|
1,500
-1.5%
|
12.45
|
US$18,675
|
|
|
2021-02-03 |
2021-02-01 |
PlS
Planned sale
|
Chief Executive Officer
Executive Director
|
2,500
-0.9%
10.69
US$26,718
|
2,500
-0.9%
|
10.69
|
US$26,718
|
|
|
2021-02-03 |
2021-02-01 |
PlS
Planned sale
|
See Remarks
Officer
|
1,500
-1.5%
11.19
US$16,785
|
1,500
-1.5%
|
11.19
|
US$16,785
|
|
|
2021-01-21 |
2021-01-19 |
PlS
Planned sale
|
Chief Executive Officer
Executive Director
|
5,000
-1.9%
13.00
US$65,000
|
5,000
-1.9%
|
13.00
|
US$65,000
|
|
|
2021-01-15 |
2021-01-15 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
2,000
-2.2%
12.25
US$24,500
|
2,000
-2.2%
|
12.25
|
US$24,500
|
|
|
2021-01-15 |
2021-01-14 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
7,000
-7.1%
11.95
US$83,650
|
7,000
-7.1%
|
11.95
|
US$83,650
|
|
|
2020-12-21 |
2020-12-17 |
S
Sale
|
Non-Executive Director
|
1,700,000
-36.6%
18.10
US$30,770,000
|
1,700,000
-36.6%
|
18.10
|
US$30,770,000
|
|
|
2020-12-21 |
2020-12-17 |
S
Sale
|
Large shareholder
|
1,700,000
-36.6%
18.10
US$30,770,000
|
1,700,000
-36.6%
|
18.10
|
US$30,770,000
|
|
|
2020-12-17 |
2020-12-15 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
1,000
-1.0%
10.48
US$10,480
|
1,000
-1.0%
|
10.48
|
US$10,480
|
|
|
2020-12-15 |
2020-12-11 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
1,405
-1.4%
10.05
US$14,120
|
1,405
-1.4%
|
10.05
|
US$14,120
|
|
|
2020-11-13 |
2020-11-11 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
595
-0.6%
10.05
US$5,980
|
595
-0.6%
|
10.05
|
US$5,980
|
|
|
2020-10-16 |
2020-10-14 |
PlS
Planned sale
|
Chief Medical Officer
Officer
|
4,000
-3.8%
10.05
US$40,200
|
4,000
-3.8%
|
10.05
|
US$40,200
|
|
|
2020-09-03 |
2020-09-01 |
S
Sale
|
Large shareholder
|
332,780
-6.6%
7.14
US$2,376,681
|
332,780
-6.6%
|
7.14
|
US$2,376,681
|
|
|
2020-05-22 |
2020-05-20 |
S
Sale
|
Large shareholder
|
420,000
-12.7%
3.66
US$1,535,562
|
420,000
-12.7%
|
3.66
|
US$1,535,562
|
|
|
2020-02-07 |
2020-02-05 |
B
Purchase
|
Chief Executive Officer
Executive Director
|
5,000
+1.9%
3.23
US$16,150
|
5,000
+1.9%
|
3.23
|
US$16,150
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
Atlas Venture Fund IX, L.P.
Large shareholder
|
100,000
+2.2%
15.00
US$1,500,000
|
100,000
+2.2%
|
15.00
|
US$1,500,000
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
Viswanathan Ravi
Large shareholder
|
133,333
+4.2%
15.00
US$1,999,995
|
133,333
+4.2%
|
15.00
|
US$1,999,995
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
Sonsini Peter W.
Large shareholder
|
133,333
+4.2%
15.00
US$1,999,995
|
133,333
+4.2%
|
15.00
|
US$1,999,995
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
Florence Anthony A. Jr.
Large shareholder
|
133,333
+4.2%
15.00
US$1,999,995
|
133,333
+4.2%
|
15.00
|
US$1,999,995
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
GRAYZEL DAVID S.
Non-Executive Director
|
100,000
+2.2%
15.00
US$1,500,000
|
100,000
+2.2%
|
15.00
|
US$1,500,000
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
New Enterprise Associates 14, L.P.
Large shareholder
|
133,333
+4.2%
15.00
US$1,999,995
|
133,333
+4.2%
|
15.00
|
US$1,999,995
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
LV Management Group, LLC
Large shareholder
|
266,000
+8.4%
15.00
US$3,990,000
|
266,000
+8.4%
|
15.00
|
US$3,990,000
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
Shanafelt Armen
Non-Executive Director
Large shareholder
|
266,000
+8.4%
15.00
US$3,990,000
|
266,000
+8.4%
|
15.00
|
US$3,990,000
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
BARRIS PETER J
Large shareholder
|
133,333
+4.2%
15.00
US$1,999,995
|
133,333
+4.2%
|
15.00
|
US$1,999,995
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
BARRETT M JAMES
Large shareholder
|
133,333
+4.2%
15.00
US$1,999,995
|
133,333
+4.2%
|
15.00
|
US$1,999,995
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
Novartis Institutes for BioMedical Research, Inc.
Large shareholder
|
766,666
+24.1%
15.00
US$11,499,990
|
766,666
+24.1%
|
15.00
|
US$11,499,990
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
KERINS PATRICK J
Large shareholder
|
133,333
+4.2%
15.00
US$1,999,995
|
133,333
+4.2%
|
15.00
|
US$1,999,995
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
SANDELL SCOTT D
Large shareholder
|
133,333
+4.2%
15.00
US$1,999,995
|
133,333
+4.2%
|
15.00
|
US$1,999,995
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
MOTT DAVID M
Large shareholder
|
133,333
+4.2%
15.00
US$1,999,995
|
133,333
+4.2%
|
15.00
|
US$1,999,995
|
|
|
2018-04-23 |
2018-04-23 |
B
Purchase
|
BASKETT FOREST
Large shareholder
|
133,333
+4.2%
15.00
US$1,999,995
|
133,333
+4.2%
|
15.00
|
US$1,999,995
|
|